Frontline Therapy of CLL: Evolving Treatment Paradigm
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
http://link.springer.com/article/10.1007/s11899-018-0438-x/fulltext.html
Reference67 articles.
1. SEER Cancer Stat Facts Chronic lymphocytic leukemia, MD http://seer.cancer.gov/statfacts/html/clyl.html . Accessed 27 Nov 2017.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. https://doi.org/10.1182/blood-2007-06-093906 .
3. •• Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. https://doi.org/10.1056/NEJMoa1509388 . This is a very important reference since it led to the FDA approval of ibrutinib as a frontline therapy in all patients with CLL—the first and only FDA-approved targeted frontline therapy in CLL.
4. • Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–76. https://doi.org/10.1016/S1470-2045(14)71182-9 . This is also a very important reference for ibrutnib, showing its efficacy in 17p- or TP53-mutated patients patients that are very difficult to otherwise treat.
5. Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood. 2012;119(19):4358–62. https://doi.org/10.1182/blood-2012-01-404681 .
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. EXABS-207-CLL Is Fixed-Duration Therapy the New Standard of Care in Frontline CLL?;Clinical Lymphoma Myeloma and Leukemia;2023-09
2. Circular RNA Expression Signatures Provide Promising Diagnostic and Therapeutic Biomarkers for Chronic Lymphocytic Leukemia;Cancers;2023-03-01
3. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia;Current Medical Research and Opinion;2020-10-29
4. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies;Expert Review of Hematology;2020-08-02
5. Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders;International Journal of Laboratory Hematology;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3